Merck Expands Biologics Testing Center in Shanghai with Completion of Phase II Facility

ShanghaiNovember 21, 2023 /PR Newswire/ -- Merck, a leading global technology company, announced its total investment last year2900The second phase of the China Biosafety Testing Experiment Center, built with an investment of tens of millions of euros, has been successfully completed and officially launched, adding to the first phase project from last year.1500Square meters. This testing laboratory is Merck's first biosafety testing facility in the Chinese market, enabling customers to access a wide range of biosafety testing services locally — from preclinical development to the cell bank characterization and batch release testing required for commercialization.

Event Guests (from left to right): Mr. Sun Hao, Manager of Biologics Safety Testing, Biopharmaceutical Testing Services, Merck Life Science; Ms. Tao Juhong, Head of Biologics Safety Operations, China, Biopharmaceutical Testing Services, Merck Life Science; Dr. Li Xinfang, CEO of Yantai MabPlex International Biopharmaceutical Co., Ltd.; Mr. Marc Jaffré, Managing Director of Merck Life Science China; Mr. Ling Gang, Chief Engineer of Pudong New Area Science and Technology and Economy Committee; Dr. Caine Leong, Head of Asia-Pacific Commercial, Biopharmaceutical Testing Services, Merck Life Science; Dr. Wang Su, Head of Commercial, China, Biopharmaceutical Testing Services, Merck Life Science; Dr. Alison Armstrong, Head of Global Technical and Scientific Solutions Team, Biopharmaceutical Testing Services, Merck Life Science.

Dirk, Global Head of Life Science Services, Merck Life Science Business·Lange (Dirk Lange) Indicates:“The opening of the Phase II laboratory further deepened our partnership with Chinese customers who are at the forefront of shaping the field of modern medicine.. Our biosafety testing laboratory center located in Shanghai can now provide services for the Chinese market with75Localized testing services with many years of international experience.”

Merck China Biosafety Testing Center Phase I Project Offers Viral Clearance Validation Services, One of the Most Critical Steps in Drug Development. Its Phase II Project Adds Cell Bank Characterization and Lot Release Testing Services to Help Biopharmaceutical Clients Ensure the Safety, Purity, and Identity of Their Cell Banks. The testing center also provides services for harvest fluid and bulk drug substance in compliance withGMPThe required batch release testing services to meet the requirements for biologics entering preclinical and clinical studies, as well as approved biologics.

With the completion of the second phase of construction, Merck in China can provide a wide range of biosafety testing services for monoclonal antibodies, other recombinant proteins, as well as cell and gene therapies. This Shanghai testing center has become an important part of Merck's global biosafety testing service network. Other centers providing this service are located in Singapore, Sterling and Glasgow in the UK, and Rockville in Maryland, USA, with all centers sharing the same global expertise, standards, and operational systems.

Merck China Biosafety Testing Laboratory Center Phase II

MerckBioReliance^®Biological safety testing services provide customers with cutting-edge innovative technologies to ensure the security and quality of the biopharmaceutical industry supply chain. As a leader in the biological safety testing industry, Merck Group has a global presence.1000Multiple clients, whose primary therapies (mAbs, ADCs, CGT, mRNA, and vaccines) boasts an industry-leading breadth of product portfolio.